For anyone in Aira searching for CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. What this means for Aira researchers is that your location matters far less than your ability to verify analytical documentation — and those quality checks are available to every researcher. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Aira researcher needs before placing a first order.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Aira comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy CJC-1295 — A Researcher's Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are operating transparently. The HPLC analytical chromatogram is the most important document in the COA: it should show a large primary peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be stated as ≥98%. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. For Aira researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Aira
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and small-scale human observations. Proper handling of CJC-1295 requires sterile reconstitution technique — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at trace quantities, and no cost saving makes omitting this acceptable. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not a licensed human medication and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
